![FILE PHOTO: An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Merck & Co Inc/Handout via REUTERS](https://newsinfo.inquirer.net/files/2021/10/2021-10-08T211543Z_4_LYNXMPEH970AQ_RTROPTP_4_HEALTH-CORONAVIRUS-SINGAPORE-PILL-620x429.jpg)
FILE PHOTO: An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Merck & Co Inc/Handout via REUTERS
JAKARTA — Indonesia has approved Merck & Co Inc’s COVID-19 antiviral pill molnupiravir for emergency use, the country’s food and drug agency said in a statement.
A batch of 400,000 pills had arrived in Indonesia, health minister Budi Gunadi Sadikin said this week. The pill was jointly developed by U.S.-based Merck and Ridgeback Biotherapeutics.
MOST READ
LATEST STORIES